Stryker Corporation (SYK)
| Market Cap | 117.81B -20.6% |
| Revenue (ttm) | 25.84B +8.5% |
| Net Income | 3.73B +27.8% |
| EPS | 9.65 +27.8% |
| Shares Out | 383.57M |
| PE Ratio | 31.83 |
| Forward PE | 19.30 |
| Dividend | $3.52 (1.15%) |
| Ex-Dividend Date | Sep 30, 2026 |
| Volume | 1,984,887 |
| Open | 305.01 |
| Previous Close | 307.08 |
| Day's Range | 305.00 - 309.57 |
| 52-Week Range | 267.00 - 389.33 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 362.62 (+18.06%) |
| Earnings Date | Oct 29, 2026 |
About SYK
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally inv... [Read more]
Financial Performance
In 2025, Stryker's revenue was $25.12 billion, an increase of 11.16% compared to the previous year's $22.60 billion. Earnings were $3.25 billion, an increase of 8.45%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for SYK stock is "Buy." The 12-month stock price target is $362.62, which is an increase of 18.06% from the latest price.
News
These 2 dividend stocks are worth owning for a lifetime
A dividend stock earns its place in a long-term portfolio by doing more than mailing shareholders a quarterly check. It needs a business that can fund those payments while investing sufficiently to st...
Stryker says Sonopet 3 receives FDA 510(k) clearance
Stryker (SYK) announced that Sonopet 3, its latest ultrasonic bone and soft tissue removal platform, has received 510(k) clearance from the U.S. FDA. The first clinical cases using Sonopet 3…
Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
Stryker has received FDA 510(k) clearance for Sonopet ® 3 , the latest evolution of its ultrasonic bone and soft tissue removal platform. Developed in collaboration with surgeons, Sonopet 3 delivers e...
Stryker price target lowered to $316 from $358 at BTIG
BTIG analyst Ryan Zimmerman lowered the firm’s price target on Stryker (SYK) to $316 from $358 and keeps a Buy rating on the shares as part of a broader research…
Stryker initiated with an Overweight at Barclays
Barclays initiated coverage of Stryker (SYK) with an Overweight rating and $375 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive rating.
Stryker price target lowered to $310 from $340 at Truist
Truist lowered the firm’s price target on Stryker (SYK) to $310 from $340 and keeps a Hold rating on the shares. Stryker’s CEO transition to Spencer Stiles is expected and…
Stryker CEO Kevin Lobo to transition to chair role, Spencer Stiles to succeed
Stryker (SYK) announced that as part of a planned succession process, Kevin Lobo will transition to the role of executive chair of the board of directors, effective January 1, 2027.
Stryker announces leadership succession
Portage, Michigan, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, today announced that as part of a planned succession process, Kevin Lobo will transiti...
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS
SAN FRANCISCO, Oct. 1, 2026 /PRNewswire/ -- On September 8, 2026, investors in Stryker Corporation (NYSE: SYK) saw the price of their shares fall $26.70 (-8.8%) after the company's CFO revealed that a...
Stryker to announce third quarter 2026 financial results
Portage, Michigan, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, October 29, 2026, to discuss its third quarter 2026 financial resu...
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Stryker price target lowered to $330 from $360 at Stifel
Stifel lowered the firm’s price target on Stryker (SYK) to $330 from $360 and keeps a Buy rating on the shares. Management highlighted two incremental, unanticipated pressures complicating the second…
Stryker price target lowered to $298 from $355 at TD Cowen
TD Cowen lowered the firm’s price target on Stryker (SYK) to $298 from $355 and keeps a Hold rating on the shares. The company’s recent public comments suggest a less…
Stryker price target lowered to $385 from $400 at Canaccord
Canaccord lowered the firm’s price target on Stryker (SYK) to $385 from $400 and keeps a Buy rating on the shares. The firm updated its model to reflect the comments…
Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
New additions advance surgical planning, implant flexibility and connected care across Stryker's Foot & Ankle portfolio Stryker is launching Prophecy® Surgical Planning for the Incompass™ Total Ankle ...
Stryker price target lowered to $360 from $399 at Citi
Citi lowered the firm’s price target on Stryker (SYK) to $360 from $399 and keeps a Buy rating on the shares. The firm updated the company’s model to reflect headwinds…
Stryker price target lowered to $348 from $418 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Stryker (SYK) to $348 from $418 and keeps an Overweight rating on the shares. The firm hosted Stryker at…
Stryker Transcript: Wells Fargo 21st Annual Healthcare Conference
Guidance for 2024 remains unchanged despite ongoing supply challenges in peripheral vascular and joint replacement segments, with robust performance in capital and trauma businesses offsetting softness. Management is confident in long-term growth, margin expansion, and the ability to regain share as supply issues resolve.
Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference
Portage, Michigan, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor, as p...
Stryker says surgical procedure completed using SportSuite Vision on Apple
Stryker (SYK) announced that the first surgical procedure using SportSuite Vision on Apple (AAPL) Vision Pro was successfully completed at Duke Health. SportSuite Vision received FDA De Novo authoriza...
Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center
SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information Stryker announced the successful completion of the first surgical procedu...
Stryker to acquire ZuriMED, terms undisclosed
Stryker (SYK) announced it has signed a definitive agreement to acquire ZuriMED, a privately held company and developer of the FiberLocker System. This transaction is subject to customary closing cond...
Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering
Portage, Mich., USA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced it has signed a definitive agreement to acquire ZuriMED, a privately held ...
Stryker to participate in the 2026 Wells Fargo Healthcare Conference
Portage, Michigan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor.
Stryker declares an $0.88 per share quarterly dividend
Portage, Michigan, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholder...